ARTICLE | Clinical News
Abgenix, Immunex to begin Phase II
April 18, 2001 7:00 AM UTC
The companies will begin a dose-escalating, North American Phase II trial in 80 kidney cancer patients of their ABX-EGF human monoclonal antibody targeting the epidermal growth factor receptor (EGFr)....